BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis

作     者：Qi Wang Wei-guo Hu Qi-bin Song Jia Wei 

作者机构：Department of Oncology Renmin Hospital of Wuhan University 

出 版 物：《Chinese Medical Sciences Journal》 (中国医学科学杂志（英文版）)

年 卷 期：2014年第29卷第4期

页      面：197-203页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：colorectal neoplasms BRAF meta-analysis 

摘      要：Objective To investigate the correlation between BRAF V600 E mutation and anti-epidermal growth factor receptor(EGFR) monoclonal antibodies(Mo Abs) therapeutic effects in metastatic colorectal cancer. Methods Studies were included into meta-analysis to investigate the association between BRAF V600 E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR Mo Abs. Results A total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total, sample sizes ranged from 67 to 493. Objective response rate(ORR), progression-free survival(PFS) and overall survival(OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS, the pooled odds ratio for ORR of mutant BRAF over wild-type BRAF was 0.27(95% CI=0.10-0.70). BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR Mo Abs(hazard ratio=2.78, 95% CI=1.62-4.76; hazard ratio=2.54, 95% CI=1.93-3.32). Conclusion BRAF V600 E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR Mo Abs.